TickerGuard
Buy Day today: Poor (44) Weak market breadth · no major macro event
SGP

SpyGlass Pharma, Inc.

Healthcare · Biotechnology

33.30$ -4.7% vs. previous close Closing price · As of: Nov 12, 2026

Ownership

Ownership Structure

Who owns SpyGlass Pharma, Inc. (SGP)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 19.4% of the shares are freely tradable; institutional investors hold 95.5%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 95.5%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 4.3%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 19.4%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 10.5%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 33Mio.

Largest Shareholders

Institutions

Institutions SGP
Name Stake (%) Shares Change (%) Date
RA Capital Management, LLC 23.98 8,021,117 +0.0 06/30/2026
NEA Management Company, LLC 22.10 7,392,301 +0.0 06/30/2026
Sands Capital Ventures, LLC 7.47 2,500,012 +0.0 06/30/2026
Samsara BioCapital, LLC 6.31 2,109,953 +0.0 06/30/2026
BlackRock Inc 2.13 711,712 +391.7 06/30/2026
T. Rowe Price Associates, Inc. 2.02 674,143 -4.3 06/30/2026
Vestal Point Capital LP 2.00 670,000 +0.5 06/30/2026
JPMorgan Chase & Co 1.88 629,739 +9.1 06/30/2026
Deerfield Management Co 1.64 550,000 +0.0 06/30/2026

Funds

Funds SGP
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 1.68 560,805 +76.9 09/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 12, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?